HB Wealth Management LLC Buys 22,867 Shares of Bristol Myers Squibb Company $BMY

HB Wealth Management LLC lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 26.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 109,993 shares of the biopharmaceutical company’s stock after buying an additional 22,867 shares during the quarter. HB Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $6,671,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Bayban bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth about $32,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research reports. Bank of America dropped their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Trading Down 0.1%

BMY stock opened at $58.05 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock has a market capitalization of $118.54 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm’s fifty day simple moving average is $56.90 and its two-hundred day simple moving average is $57.49.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business earned $1.80 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.